Equities research analysts at B. Riley began coverage on shares of AMAG Pharmaceuticals (NASDAQ:AMAG) in a research note issued on Thursday, December 7th, MarketBeat reports. The brokerage set a “neutral” rating and a $16.00 price target on the specialty pharmaceutical company’s stock. B. Riley’s target price would indicate a potential upside of 20.75% from the stock’s previous close.
AMAG has been the subject of several other reports. Jefferies Group reiterated a “buy” rating and set a $16.00 price target on shares of AMAG Pharmaceuticals in a research report on Sunday, November 5th. Piper Jaffray Companies initiated coverage on AMAG Pharmaceuticals in a research report on Monday, October 23rd. They issued a “neutral” rating and a $18.00 price objective for the company. Zacks Investment Research cut AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 24th. BidaskClub cut AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. Finally, Deutsche Bank reaffirmed a “hold” rating and issued a $24.00 price target on shares of AMAG Pharmaceuticals in a research note on Thursday, August 31st. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $23.38.
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) traded down $0.20 during trading hours on Thursday, hitting $13.25. The stock had a trading volume of 649,814 shares, compared to its average volume of 666,648. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59. The stock has a market capitalization of $475.79, a PE ratio of -2.18 and a beta of 0.79. AMAG Pharmaceuticals has a 1 year low of $11.93 and a 1 year high of $36.60.
COPYRIGHT VIOLATION WARNING: “AMAG Pharmaceuticals (AMAG) Coverage Initiated at B. Riley” was first posted by Week Herald and is the property of of Week Herald. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://weekherald.com/2017/12/30/amag-pharmaceuticals-amag-earns-neutral-rating-from-analysts-at-b-riley.html.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.